H2AZ1 and prostate carcinoma: Indeed, an AR responsiveness persists in the androgen-dependent to -independent transition of prostate cancer [136] and, with its co-activator SRCAP, AR could potentially bring the over-expressed H2A.Z.1 to different promoters.